"FDA approves AbbVie’s Emblaveo for intra-abdominal infections" was originally created and published by Pharmaceutical ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

and complicated intra-abdominal infections (cIAI). Ed Cox, director for the Office of Antimicrobial Products at the FDA, said that Recarbrio should be “reserved for situations when there are ...

This approval is a significant step in combating serious infections caused by aerobic Gram-negative organisms. The authorisation covers the use of EMBLAVEO for complicated intra-abdominal ...

This column describes a ventral abdominal approach for castration in ... collar on the rat and begin antibiotics for secondary infection. Complications associated with castration include hematoma ...